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ABSTRACT  
Objective: This study was undertaken with the aim of the formulation and evaluation of hypothalamic hormone somatostatin analogue tablets, 
which are intended for neuroendocrine tumours treatment. 
Methods: Tablets were prepared by using the wet granulation method and evaluated for weight variation, resistance to crushing, friability, 
disintegration time, content and content uniformity. Stability tests have been performed. 
Results: Characteristics of somatostatin analogue cyphetrylin powder have been investigated, and the wet granulation method has been chosen to 
prepare tablets. Technical pharmaceutical properties of formulations of different compositions and obtained tablets were estimated and the best 
formulation CF11 has been established with appropriate characteristics: disintegration time less than 15 min, resistance to crushing more than 30 
kg·m·s−2
Conclusion: Because of somatostatin analogue cyphetrylin powder properties tablets were prepared by the wet granulation method with starch, 
lactose, povidone, talc, microcrystalline cellulose, calcium stearate and magnesium stearate as excipients. The best formulation including povidone 
has characteristics corresponding to requirements of European Pharmacopoeia (PhEur) and State Pharmacopoeia of the Russian Federation 
(PhRu). Examination of cyphetrylin tablets showed its quality and stability within the time of observation–12 mo. 
, weight variation ˂ 7 .5 %, active substance content closed to the nominal quantity and consistent cyphetrylin distribution in the batch. 
Performed examinations showed cyphetrylin tablets stability in the long-term study. 
Keywords: Somatostatin analogue, Cyphetrylin, Tablets, Formulations, Pharmaceutical technical characteristics, Content and content uniformity, 
Stability studies 




Neuroendocrine Tumours (NET) are rare human tumour arising 
from the cells of the diffuse neuroendocrine system located in 
various organs and tissues of the human body (gastrointestinal tract, 
lungs, pituitary gland, etc.). This type of tumours is characterized by 
the presence of secondary symptoms caused by metabolically active 
substances hyperproduction and secretion [1, 2].  
Biotherapy with Somatostatin Analogues (SSA) has a proven effect in 
the treatment of clinical syndromes (carcinoid syndrome, 
hypoglycemia syndrome, Zollinger-Ellison syndrome, etc.). The 
drugs in this group (most widely used three SSA are as follows: 
octreotide, lanreotide and pasireotide) suppress clinical symptoms 
and reduce the level of biochemical tumour markers and also have 
useful anti-proliferative activity [3, 4]. 
Several SSAs has been synthesised in N.N. Blokhin NMRCO, including 
cytotoxic SSAs, and their antitumor effect has been studied in the 
experiments in vitro and in vivo. According to the results of the 
preliminary investigations, a hypothalamic hormone somatostatin 
analogue cyphetrylin has been selected for a preclinical study. 
Cyphetrylin is pentapeptide (Boc-Cys(Thp)-Phe-D-Trp-Lys(Z)-Thr-
OMe) with noncyclic structure [5].  
Usually, parenteral way of administration is used for peptide drug 
administration because of their enzymatic instability [6, 7]. But 
cyphetrylin is insoluble in water, and it is metabolically stable in the 
gastric fluid because of reactive groups blocking. The specific studies 
of cyphetrylin in vivo showed its high antitumor efficiency on animal’s 
experimental tumours and xenografts by oral administration [8, 9]. 
The objective of the present study was to create hypothalamic 
hormone analogue cyphetrylin dosage form composition and 
preparation method and to evaluate obtained pharmaceutical by 
different parameters according to requirements of current editions 
of PhEur and PhRu [10, 11]. 
This investigation is the first attempt to obtain a dosage form of new 
original somatostatin analogue for oral administration.  
MATERIALS AND METHODS  
Materials 
Cyphetrylin substance was obtained from chemical synthesis 
laboratory of N.N. Blokhin NMRCO, potato starch, lactose (because 
cyphetrylin isn’t sensitive to moisture we used lactose monohydrate 
[12]), povidone, talc, microcrystalline cellulose, calcium stearate and 
magnesium stearate were purchased from different suppliers and 
conformed to PhEur requirements. All other used chemicals and 
solvents were of analytical grade.  
Methods 
Bulk density  
2 g of cyphetrylin powder or cyphetrylin granulate previously lightly 
shaken to break any agglomerates formed was introduced into a 10 
ml measuring cylinder. After the initial volume was observed, then 
calculate the bulk density using the following formula [10, 11].  
Bulk Density =
 Weight of the powder
Bulk volume
 
Angle of repose 
The angle of repose of cyphetrylin granulate was determined by the 
fixed funnel method. The accurately weighed powder was taken in a 
funnel. The height of the funnel was adjusted in such a way that the 
tip of the funnel just touched the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the 
surface. The diameter of the powder cone was measured, and the 





Where, θ = angle of repose,  
h = height of the pile,  
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r = radius of the pile base  
Weight variation test  
To study weight variation 20 tablets of each formulation were 
weighed using an electronic analytical balance. The average weight 
was calculated, then individual tablet weight was compared with 
average weight [10, 11]. 
Disintegration time  
The examination of disintegration time was carried on randomly 
selected six tablets of each formulation without disks. The purified 
water was used as a disintegration medium and temperature was 
maintained at 37±0.5 °C. The average disintegration time of six 
tablets was noted down for calculation [10, 11].  
Resistance to crushing and friability 
The test of resistance to crushing was measured on tester consists of 
two jaws facing each other, one of which moves towards the other. 
The tester is calibrated with the precision of kg·m·s−2
An analytical method for cyphetrylin assay in tablets  
. The 
measurement is carried out on ten tablets [10, 11]. 
The friability test was performed by using tablet friability tester 
Erweka (Germany). Ten tablets were accurately weighed and placed 
in the tester and operated for 100 revolutions. The tablets were 
dedusted and reweighed, and friability was calculated using the 
following equation.  
Friability =
Initial weight − Final weight
Initial weight
 x 100 
The analytical method for cyphetrylin assay in tablets has been 
created and validated [13, 14]. Cyphetrylin content under 
formulation developed was estimated with Carry 100 UV-Visible 
spectrophotometer (USA). The specially synthesised cyphetrylin 
substance of 99.0 % of the active ingredient was used as a standard 
sample.  
About 100 mg of cyphetrylin rubbed tablets were dissolved in 50 ml 
of ethanol (0.12 mg/ml) and filtered via Millipore with pore size 
0.45 μm. The absorbance of this solution was measured at the 
maximum wavelength of cyphetrylin of 282±2 nm. The absorbance 
of the cyphetrylin standard spirituous solution of the same 
concentration was measured in parallel. Cyphetrylin quantity 
calculation was carried out by a formula taking into consideration 
dilutions of all solutions and cyphetrylin content in substance. 
Uniformity of drug content 
The determination was performed for ten tablets separately by UV-
spectrophotometry method described for assay test. 25 ml of 95 % 
ethyl alcohol were added to each tablet and shook intensively during 
8-10 min. The liquid was filtered, and the drug content was 
determined after appropriate dilution with 95 % ethyl alcohol.  
RESULTS AND DISCUSSION  
Characterization of powder 
The general technological properties of cyphetrylin powder 
mentioned in table 1. 
 
Table 1: Technological characteristics of cyphetrylin powder 
№  Technological characteristics  Results 
1. Particle size 0.1 mm and less–86 % 0.1–0.25 mm–4 % More than 0.25 mm-10 % 
2. Particles form  Circular Needle-like crystal Spherical conglomerate 
3. Wettability Doesn’t get wet 
4. Bulk density* 0.09±0.01 g/ml 
5. Flowability*  0.1±0.02 g/s 
*All values are expressed as mean±SD, n=6  
 
It is visible that cyphetrylin powder is polydisperse-its particles are 
of different form and size (table 1). The fraction with a particle size 
less 0.25 mm is more than half, that way it is necessary to use 
excipients to increase particle size and mass and flowability. The 
substance doesn’t get wet, and it means that it is required to include 
appropriate excipients to control tablets disintegration. 
To improve cyphetrylin powder properties (at first flowability) we 
decided to use wet granulation. Because cyphetrylin is insoluble in 
water, but the mixture of cyphetrylin and excipients is well wettable 
by water, 5% starch paste and 1% and 2% povidone solution were 
tested as granulation agents. 
To prepare granulate of cyphetrylin the mixtures of active substance 
and excipients (for 20 tablets) were wetted by starch paste or 1% or 
2 % povidone solution and dried to complete drying out. When 
dried, granulates were passed through a mesh sieve #710, powder 
mixture (magnesium stearate, talc and starch) was added to the 
blend and compressed into tablets on eccentric tablet press Erweka 
(Germany) using 6 mm punch. 
Formulations with the different correlation of ingredients have been 
prepared (table 2). The cyphetrylin dose in all tablets was 6 mg. As it 
was shown by a series of biological experiments in vivo, it is required 
cyphetrylin quantity to demonstrate antitumor efficiency and safety. 
 
Table 2: Composition cyphetrylin formulation for tablets 
Ingredients, mg/tab  Formulation code 
CF1 CF2 CF3 CF4 CF5 CF6 CF7 CF8 CF9 CF10 CF11 
Cyphetrylin 6 6 6 6 6 6 6 6 6 6 6 
Lactose 50 30 35 45 50 50 55 60 60 55 55 
Microcrystalline cellulose 25 35 15 20 15 10 10 10 5 10 5 
Starch 10 20 35 25 25 30 25 25 25 20 25 
Povidone  5 
Powder blend (magnesium stearate, talc and starch) 10 10 10 10 10 10 10 10 10 10 10 
CF–cyphetrylin formulation 
 
All granulates (table 2, formulations 1-7) possess sufficient flow 
properties and good packing ability. The best with necessary 
flowability (3.0 g/s), bulk density (0.15 g/ml) and angle of 
repose (40.8±1.1 °) was mixture №7. But resistance to crushing 
of tablets obtained from this formulation was insufficient (table 
4) and didn’t meet to the recommendations of PhRu [11], so we 
continued to create tablet formulation (table 2, formulations 8-
11).  
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The flow properties of the final blend were tested by measuring bulk 
density, flowability and the angle of repose and they were found to 
be the best for CF11 formulations. As is seen from table 3, povidone 
inclusion into formulation led not only to sufficient flow 
characteristics but to the optimal correlation between resistance to 
crushing and disintegration. 
Experimental tablets were prepared by tablet press Erweka 
(Germany). All the prepared formulations were evaluated for 
different physicochemical properties for physical parameters: 
appearance, resistance to crushing, friability, disintegration, 
average weight, weight variation, and results are presented in 
table 4. 
 
Table 3: Characteristics of formulation CF11 and obtained tablets 
Formulation (CF11) Tablets (CF11)* 
Bulk density* Flowability (g/ml) * Angle of repose (g/s) * Disintegration ( °) * Resistance to crushing# (kg·m·s (min) −2) 
0.49±0.01  6.43±0.02  40.8±1.1 9.3±1.2  38.3±2.3 
*All values are expressed as mean±SD, *n=6, #n=10 
 
Appearance and test of weight variation may be the most 
straightforward indicators of technology compliance. The 
appearance of prepared cyphetrylin tablets was high-quality (white, 
straight, circular, 6 mm diameter, biconvex tablets) except 
formulations CF2, CF3 and CF9, which surfaces were off-white and 
slightly marbled (of unequal colour). 
The examination of weight variation showed that average weight of 
cyphetrylin tablets of all compositions was within the range of 
calculated mass±10 %, and maximum weight variation was 7.29%, 
which was in PhEur and PhRu limits of±7.5%. 
Tablet mechanical characteristics provide their stability within the 
manufacture and useful quality. Tablets must pass these points, and 
tablet defects are nonaccepted.  
The results of prepared tablets in the test of resistance to crushing 
were in the range of 7.32 to 38.32 kg·m·s−2 but only composition 
CF11 resistance to crushing (38.32±0.12 kg·m·s−2) corresponded to 
PhRu recommendations-minimal value has to be not less than 30 
kg·m·s−2
The friability test for compositions CF2, CF3, CF6 and CF9 was more 
than the limit (1 %), but other compositions friability was less what 
is illustrative of tablets good mechanical resistance. 
 for tablets of this diameter. At the same time, disintegration 
test for CF11 composition was successful, and tablets passed the test 
(less than 15 min).  
All formulations passed the disintegration test by taking time (not 
more than 15 min). Formulations CF4, CF6 and CF10 have shown 
disintegration time near to the limit, but formulations CF2 and CF9 
had disintegration time lower than ideal. 
 
Table 4: Pharmaceutical technical characteristics of cyphetrylin tablets 
Formulation 
code 










CF1 White straight tablets 10.79±0.28 0.91 8 98.62±7.28 5.48 
СF2 Off-white straight tablets, 
unequal colored 
7.32±0.43 1.20 3 107.89±9.31 7.12 
СF3 Off-white straight tablets, 
unequal colored 
8.99±0.37 1.15 6 103.46±6.44 6.49 
CF4  White straight tablets 17.76±0.11 0.83 14 94.67±8.89 6.32 
CF5 White straight tablets 14.40±0.29 0.99 9 102.38±7.96 5.67 
CF6 White straight tablets 15.04±0.59 1.08 11 100.31±4.96 7.29 
CF7 White straight tablets 19.60±0.15 0.98 9 106.99±10.16 4.67 
CF8 White straight tablets 14.76±0.18 0.94 8 112.43±7.92 6.39 
CF9 Off-white straight tablets, 
unequal colored 
7.50±0.64 1.12 3 101.49±9.42 5.08 
CF10 White straight tablets 24.81±0.21 0.96 12 98.32±6.29 6.75 
CF11  White straight tablets 38.32±0.12 0.93 9,3 102.39±6.71 5.86 
*All values are expressed as mean±SD, n=6, *n=20, #n=10 
 
As is seen from table 4 above, investigations revealed that CF11 
formulation with povidone addition has an optimal correlation of 
mechanical properties and disintegration. 
Assay and content uniformity  
Because cyphetrylin dose in the tablet is 6 mg (less than 6 %), the 
quantity of the active substance in each tablet is the most critical 
parameter. And according to the requirement of PhEur and PhRu, it 
is necessary to determine the uniformity of drug content. The test 
was carried out on ten tablets by direct estimation of each unit. The 
conditions of determination were equal to the assay test. 
Results of quantitative determinations of two cyphetrylin tablets 
batches are presented in table 5. Each point is an average of six 
determinations.
 
Table 5: Results of content estimations for cyphetrylin tablets 6 mg 
Batch Cyphetrylin content (mg) Content uniformity 
010317 𝑋𝑋� = 6.0  
S = 0.1072 Δx = 0.099 
t(p,f)calc 
𝜺𝜺� = 1.66 % 
= 0.459 
 
n=10 k(f,P) = 2.4  
S = 3.8453 
𝑋𝑋� = 96.1 ˂ 98.5 
M (Reference value) = 98.5  
AV(Acceptance value), % = 11.6 ˂ 15.0  
041117 𝑋𝑋� = 5.9  
S = 0.1018 Δx = 0.093 
t(p,f)calc 
𝜺𝜺� = 1.57 % 
= 0.260 
 
n=10 k(f,P) = 2.4  
S = 4.6932 
𝑋𝑋� = 95.2 ˂ 98.5 
M (Reference value) = 98.5  
AV(Acceptance value), % = 11.3 ˂ 15.0 
As it is seen from table 5, tests have shown the consistency of active substance content in the tablet and cyphetrylin distribution in the batch. 
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Cyphetrylin tablets stability studies were performed to evaluate chosen 
formulation physical and chemical attributes in a long-term study at 25 
°C/60% RH. The table 6 data show that all characteristics of the 
preparation are stable during the time of storage (12 mo). 
 
Table 6: Results of cyphetrylin tablets 6 mg stability tests 
Batch №  Time Disintegration (min) Content (mg) 
Limits by specification 
Not more than 15  From 5.4 to 6.6 
010317  0 8 6.4 
3 mo 8 6.5 
6 moths 7 6.3 
9 mo 8 6.4 
12 mo 8 6.3 
021117 0 9  6.0 
3 mo 8 6.0 
6 moths 8 5.9 
9 mo 9 5.9 
12 mo 8 5.8 
031117 0 7 5.5 
3 mo  7 5.5 
6 moths  8 5.5 
9 mo 7 5.6 
12 mo 7 5.4 
 
CONCLUSION  
Because of somatostatin analogue cyphetrylin powder 
characteristics, tablets were prepared by wet granulation method 
with starch, lactose, povidone, talc, microcrystalline cellulose, 
calcium stearate and magnesium stearate as excipients.  
The best formulation including povidone has characteristics 
corresponding to the requirements of European Pharmacopoeia and 
State Pharmacopoeia of the Russian Federation: disintegration time 
less than 15 min, resistance to crushing more than 30 kg·m·s−2
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